Dermira, Inc. (NASDAQ: DERM) filed an S-1 form with the Securities and Exchange Commission (SEC) for a secondary offering. There were no terms given in this initial filing but the proposed maximum price is estimated at $97.75 million but this is really just a placeholder.
The underwriters for this offering are Leerink Partners, Cowen, Needham, and Guggenheim.
Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. The management team has extensive experience in product development and commercialization, having served in leadership roles at several leading dermatology companies.
Its strategy is to leverage this experience to in-license, acquire, develop and commercialize products that Dermira believes can be successful in the dermatology marketplace. The company has a portfolio of five product candidates targets significant market opportunities and includes three late-stage product candidates: Cimzia (certolizumab pegol), for the treatment of moderate-to-severe plaque psoriasis; DRM04, for the treatment of hyperhidrosis, or excessive sweating; and DRM01, for the treatment of acne.
The company is currently focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as psoriasis, hyperhidrosis and acne. These diseases impact millions of people worldwide and can have significant, multidimensional effects on patients’ quality of life, including their physical, functional and emotional well-being.
Finally, Dermira currently intends to use the net proceeds from this offering for external research and development expenses associated with the development of Cimzia, DRM04 and DRM01 product candidates, with the balance primarily used to fund internal research and development expenses associated with all of the product candidates, working capital, capital expenditures and other general corporate purposes.
ALSO READ: How The Biggest Biotech IPO Did In Its Debut
Shares of Dermira closed Tuesday up 0.2% at $24.37 on a 52-week trading range of $12.68 to $25.24. The stock has a consensus analyst price target of $24.75.
Is Your Money Earning the Best Possible Rate? (Sponsor)
Let’s face it: If your money is just sitting in a checking account, you’re losing value every single day. With most checking accounts offering little to no interest, the cash you worked so hard to save is gradually being eroded by inflation.
However, by moving that money into a high-yield savings account, you can put your cash to work, growing steadily with little to no effort on your part. In just a few clicks, you can set up a high-yield savings account and start earning interest immediately.
There are plenty of reputable banks and online platforms that offer competitive rates, and many of them come with zero fees and no minimum balance requirements. Click here to see if you’re earning the best possible rate on your money!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
